Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective

Neuro-Oncology

Volumn 15, Issue 8, 2013, Pages 1017-1026

  Wiestler, Benedikt ^a,b   Claus, Rainer ^a   Hartlieb, Sabine A ^a   Schliesser, Maximilian G ^a   Weiss, Elisa K ^a,b   Hielscher, Thomas ^a   Platten, Michael ^a,b   Dittmann, Laura M ^a   Meisner, Christoph ^c,d   Felsberg, Jörg ^e   Happold, Caroline ^j   Simon, Matthias ^f   Nikkhah, Guido ^g   Papsdorf, Kirsten ^h   Steinbach, Joachim P ⁱ   Sabel, Michael ^e   Grimm, Christiane ^a,b   Weichenhan, Dieter ^a   Tews, Björn ^a   Reifenberger, Guido ^e   Capper, David ^a,b   Müller, Wolf ^a,b   Plass, Christoph ^a   Weller, Michael ^j   Wick, Wolfgang ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

ⁱ GOETHE UNIVERSITY   (Germany)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

APNG methylation; G CIMP; glioblastoma; H3F3A mutation; IDH mutation; PRDX1 methylation

Indexed keywords

BIOLOGICAL MARKER; CYTOSINE; GUANINE; HISTONE H3; ISOCITRATE DEHYDROGENASE 1; PEROXIREDOXIN 1; PHOSPHATE; TEMOZOLOMIDE;

AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DNA METHYLATION; GENETIC ASSOCIATION; GERIATRIC DISORDER; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MUTATION; PHENOTYPE; PREVALENCE; PROMOTER REGION; TREATMENT OUTCOME; WILD TYPE;

APNG METHYLATION; G-CIMP; GLIOBLASTOMA; H3F3A MUTATION; IDH MUTATION; PRDX1 METHYLATION;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880678757     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not043     Document Type: Article

References (35)

1. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns ofcare in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628-634.
2. Weller M, Platten M, Roth P, Wick W. Geriatricneuro-oncology: frommy-thology to biology. Curr Opin Neurol. 2011;24(6):599-604.
3. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2012;39(4):350-357.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
5. Sijben AE, McIntyre JB, Roldan GB, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neuro-oncol. 2008;89(1):97-103.
6. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Rad Oncol Biol Phys. 2010;76(3):S20-S27.
7. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Rad Oncol Biol Phys. 2006;65(2):499-508.
8. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527-1535. (Pubitemid 46588417)
9. Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer. 2004;100(10):2208-2214. (Pubitemid 38580342)
10. Gallego Perez-Larraya J, Ducray F, Chinot O, et al. Temozolomide inelderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):3050-3055.
11. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707-715.
12. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897): 1807-1812.
13. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
14. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
15. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
16. Schwartzentruber J, Korshunov A, Liu XY, et al. Drivermutationsinhistone H3.3 and chromatin remodelling genesinpaediatric glioblastoma. Nature. 2012;482(7384):226-231.
17. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-437.
18. Agnihotri S, Gajadhar AS, Ternamian C, et al. Alkylpurine-DNA-N- glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 2012;122(1):253-266.
19. Dittmann LM, Danner A, Gronych J, et al. Downregulation of PRDX1 by promoter hypermethylationisfrequentin1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro. Oncogene. 2011;31:3409-3418.
20. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Nat Acad Sci U S A. 2005;102(44): 15785-15790. (Pubitemid 41552820)
21. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4): 547-560.
22. Du P, Zhang X, Huang CC, et al. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinform. 2010;11:587.
23. Grambsch PM, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
24. Lausen B, Hothorn T, Bretz F, Schumacher M. Optimally selected prognostic factors. Biomet J. 2004;46:364-374.
25. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73-85.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc B. 1995;57:289-300.
27. RDevelopment Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
28. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10(1 Pt 1):228-233. (Pubitemid 38114184)
29. Jha P, Suri V, Singh G, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagnost Mol Pathol B. 2011;20(4):225-232.
30. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474-478.
31. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-483.
32. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
33. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-5750.
34. Hegi ME, Diserens AC, Gorlia T, et al. MGMT genesilencing and benefitfrom temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
35. Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009;5(8):e1000602.